JP2013531679A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013531679A5 JP2013531679A5 JP2013518765A JP2013518765A JP2013531679A5 JP 2013531679 A5 JP2013531679 A5 JP 2013531679A5 JP 2013518765 A JP2013518765 A JP 2013518765A JP 2013518765 A JP2013518765 A JP 2013518765A JP 2013531679 A5 JP2013531679 A5 JP 2013531679A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- formulation
- seq
- amino acid
- antibody fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36120910P | 2010-07-02 | 2010-07-02 | |
| US61/361,209 | 2010-07-02 | ||
| PCT/US2011/042838 WO2012003470A2 (en) | 2010-07-02 | 2011-07-01 | Antibody formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015166305A Division JP2016026164A (ja) | 2010-07-02 | 2015-08-26 | 抗体製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013531679A JP2013531679A (ja) | 2013-08-08 |
| JP2013531679A5 true JP2013531679A5 (enExample) | 2014-08-14 |
Family
ID=45402685
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518765A Pending JP2013531679A (ja) | 2010-07-02 | 2011-07-01 | 抗体製剤 |
| JP2015166305A Pending JP2016026164A (ja) | 2010-07-02 | 2015-08-26 | 抗体製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015166305A Pending JP2016026164A (ja) | 2010-07-02 | 2015-08-26 | 抗体製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8754195B2 (enExample) |
| EP (1) | EP2588141A4 (enExample) |
| JP (2) | JP2013531679A (enExample) |
| CN (1) | CN103108658B (enExample) |
| AU (2) | AU2011274363A1 (enExample) |
| BR (1) | BR112012033457A2 (enExample) |
| CA (1) | CA2803998A1 (enExample) |
| SG (1) | SG186421A1 (enExample) |
| WO (1) | WO2012003470A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| SG11201407779YA (en) * | 2012-06-21 | 2015-02-27 | Ucb Pharma Sa | Pharmaceutical formulation |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| SI3049441T1 (sl) * | 2013-09-27 | 2020-03-31 | F. Hoffmann-La Roche Ag | Formulacije protiteles proti PD-L1 |
| JP6799904B2 (ja) * | 2014-07-31 | 2020-12-16 | キユーピー株式会社 | 含水エタノール製剤及びその製造方法、並びに、リゾチーム加工品及び／又はその塩並びにその製造方法 |
| WO2016077451A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| EP3380525B1 (en) | 2015-11-25 | 2023-11-08 | Immunogen, Inc. | Pharmaceutical formulations and methods of use thereof |
| EP3383435A4 (en) | 2015-11-30 | 2019-07-10 | Medimmune, LLC | OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS |
| EA201891164A1 (ru) | 2015-12-16 | 2018-11-30 | Ридженерон Фармасьютикалз, Инк. | Композиции и способы получения белковых микрочастиц |
| CN105920600A (zh) * | 2016-04-19 | 2016-09-07 | 上海景泽生物技术有限公司 | 一种稳定的抗vegf抗体制剂及其用途 |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| JP2024502825A (ja) | 2020-12-30 | 2024-01-23 | エーマックス バイオ， インコーポレイテッド | 抗体の局所的延長放出 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5468468A (en) | 1989-02-09 | 1995-11-21 | The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services | Method for making a monoclonal antibody, monoclonal antibodies to α PD |
| EP0456766B1 (en) | 1989-02-09 | 1999-04-28 | The United States Of America | TYPE oc PLATELET-DERIVED GROWTH FACTOR RECEPTOR GENE |
| DK0584082T3 (da) | 1991-01-31 | 2000-10-16 | Univ California | Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider |
| IE920318A1 (en) | 1991-01-31 | 1992-07-29 | Univ California | Human platelet-derived growth factor receptors |
| US5444151A (en) | 1992-05-15 | 1995-08-22 | Ludwig Institute For Cancer Research | Platelet derived growth factor antagonists |
| PT1516628E (pt) * | 1995-07-27 | 2013-09-24 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US5882644A (en) | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
| EP0852951A1 (de) * | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| DK0999853T3 (da) * | 1997-06-13 | 2003-04-22 | Genentech Inc | Stabiliseret antostofformulering |
| AU4592601A (en) | 2000-03-21 | 2001-10-03 | Millennium Predictive Medicine | Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer |
| PT1324776E (pt) * | 2000-10-12 | 2009-12-23 | Genentech Inc | Formulações de proteína concentradas de viscosidade reduzida |
| WO2003009817A2 (en) * | 2001-07-25 | 2003-02-06 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| WO2003068260A1 (fr) * | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| MXPA05005925A (es) | 2002-12-02 | 2006-02-08 | Abgenix Inc | Anticuerpos dirigidos a la fosfolipasa a2 y sus usos. |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| US20080199438A1 (en) | 2004-03-16 | 2008-08-21 | Dnavec Research Inc. | Methods For Suppressing Tumor Proliferation |
| CN101287761A (zh) * | 2005-06-15 | 2008-10-15 | 先灵公司 | 抗-igf1r抗体制剂 |
| PT2100618E (pt) * | 2005-06-17 | 2014-04-07 | Philadelphia Health & Educatio | Um anticorpo anti-pdgfr-alfa para o tratamento de cancro ósseo metastático |
| EP2029163A4 (en) * | 2006-06-14 | 2010-08-11 | Imclone Llc | LYOPHILIZED FORMULATIONS OF ANTI-EGFR ANTIBODIES |
| CL2007002225A1 (es) * | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
| CA2665567C (en) * | 2006-10-06 | 2012-07-03 | Amgen Inc. | Stable formulations |
| US20080153818A1 (en) * | 2006-12-21 | 2008-06-26 | Bingaman David P | Methods for preventing inflammation during surgery |
-
2011
- 2011-07-01 CA CA2803998A patent/CA2803998A1/en not_active Abandoned
- 2011-07-01 BR BR112012033457A patent/BR112012033457A2/pt not_active IP Right Cessation
- 2011-07-01 AU AU2011274363A patent/AU2011274363A1/en not_active Abandoned
- 2011-07-01 WO PCT/US2011/042838 patent/WO2012003470A2/en not_active Ceased
- 2011-07-01 SG SG2012094074A patent/SG186421A1/en unknown
- 2011-07-01 CN CN201180042125.5A patent/CN103108658B/zh not_active Expired - Fee Related
- 2011-07-01 US US13/175,522 patent/US8754195B2/en not_active Expired - Fee Related
- 2011-07-01 JP JP2013518765A patent/JP2013531679A/ja active Pending
- 2011-07-01 EP EP11801508.0A patent/EP2588141A4/en not_active Withdrawn
-
2015
- 2015-08-26 JP JP2015166305A patent/JP2016026164A/ja active Pending
-
2016
- 2016-02-29 AU AU2016201291A patent/AU2016201291A1/en not_active Abandoned